HLB bioStep CEO Baek Seongjin Increases Stake to 0.06% via Open Market Purchase… Small but Positive Signal of Management Confidence
On May 29, 2026, HLB bioStep CEO Baek Seongjin purchased 5,000 common shares at 3,800 KRW per share through open market trading, increasing his total holdings to 10,000 shares (0.06% stake).
Compared to the previous report (May 8), his ownership doubled from 0.03% to 0.06%, with the purchase price (3,800 KRW) representing a ~2.3% premium over the base date closing price (3,715 KRW).
This small but voluntary insider purchase by the largest shareholder and CEO signals management confidence in the company's future value, which can be interpreted as a positive signal to the market.
However, the scale of the purchase is minimal relative to total shares outstanding (17.43 million shares), increasing stake by only 0.03 percentage points, so the direct impact on short-term stock price is limited. The signal strength would be enhanced if followed by additional purchases or shareholder return policies such as share buybacks.
KOSDAQ Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders